San Francisco Bay Area biotech stories.
Thursday, February 17, 2011
Debt conversion pushes BioMarin to $12.2M in Q4 loss
BioMarin Pharmaceutical Inc. lost $12.2 million in the December quarter, compared with a $4.7 million profit a year earlier.
The company’s revenue rose to $101.6 million in the quarter, up from $87.1 million a year earlier.
BioMarin (NASDAQ: BMRN), based in Novato, blamed the fourth quarter loss on $13.7 million in debt conversion expenses.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)